Alirocumab reduces MIs
Apr 12, 2019•8 min•Ep. 45
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
This week in clinical cardiology:
- Alirocumab reduces both type 1 and 2 MIs.
- Despite failed primary endpoint, MI alert device has predictive value.
- Look for alcohol septal ablation in the next HOCM guideline.
- FDA: Forty ARBs free of nitrosamines.
You can contact the Cardiocast with ideas, suggestions, stories, or questions for Dr. Dwyer by emailing us at podcasts@mdedge.com and you can follow MDedge Cardiology on Twitter at @MDedgeCardio.
For the best experience, listen in Metacast app for iOS or Android